Materna Medical Announces Ellora™ and Additional Close on $20M Series B2
"As we celebrate the addition of these new funds to our investment team, we are also excited to announce the new commercial name for our second product, Ellora™ (formerly Materna Prep), aiming to transform the standard of care in labor and delivery," commented Tracy MacNeal, Chief Executive Officer for Materna Medical "Over 20 of the top hospitals in the US have been incredible partners in the EASE trial for Ellora™, which will be the basis of our FDA De Novo submission this summer."
For more information on Materna Medical, visit MaternaMedical.com.
About Materna Medical
Materna Medical is a novel OBGYN platform company defining a $25B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical's mission is to empower women to protect their pelvic health.
Our first product, Milli™, is vaginal dilator to support patients suffering from vaginismus and related painful sex. In 2019, the Milli device launched as a wellness trainer and, in 2023, received FDA clearance to sell over the counter, enabling streamlined access to people suffering from vaginismus. Milli outcomes have been studied in a post-market prospective virtual study named POMPOM.
Materna's second product, Ellora™, is an investigational device used during labor and is intended to reduce pelvic floor muscle injury during vaginal delivery. This product is being studied in the EASE trial, a large, randomized controlled trial in 20 top US hospitals. Materna aims to transform the standard of care in labor and delivery by protecting pelvic floor health for moms.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Mellow Sleep Redefines Comfort with a Revolutionary New Cloud Pillow
Dover, Aug. 12, 2025 (GLOBE NEWSWIRE) — DOVER, DE – August 11, 2025 – Mellow Sleep, a leader in sleep ergonomics and material science, today announced the launch of a revolutionary new cloud pillow designed to permanently solve the universal problem of restless, unfulfilling sleep. This launch marks a new era for sleep wellness, moving beyond one-size-fits-all solutions to offer a truly personalized and restorative experience. The frustrating, nightly search for a pillow that is 'just right' is finally over. Millions of people struggle with pillows that are too firm, too soft, too high, or too low, leading to neck pain, shoulder stiffness, and persistent fatigue. This nightly battle for comfort often involves folding, bunching, or stacking pillows in a desperate attempt to find support. Mellow Sleep addresses this issue at its core with a groundbreaking cloud pillow that intelligently adapts to the sleeper. This innovative pillow solves sleep discomfort through its proprietary 3-zone contour design. Each zone is meticulously engineered for a distinct biomechanical purpose. The central contour cradles the head with gentle, pressure-relieving support, while the raised outer edges are optimized for side sleepers, filling the gap between the shoulder and neck. The third zone provides a specialized cervical ramp that delivers a targeted lift, ensuring the spine maintains a natural and healthy alignment throughout the night. This integrated system prevents the awkward angles that lead to morning aches and pains. 'Our goal was to create the perfect cloud pillow by listening to the real-world frustrations of sleepers,' said Jay Yue, founder of Mellow Sleep. 'People are tired of compromising. They shouldn't have to choose between a soft feel and firm support. We spent years researching materials and ergonomics to find a way to deliver both. The result is our new CloudAlign™ Pillow, a product we believe sets a new industry standard for what a pillow can and should do for your well-being. It's more than just a place to rest your head; it's an investment in your health.' At the heart of this exceptional Mellow Sleep cloud pillow is the CloudSoft Core™, a proprietary shape-retaining memory foam. Unlike conventional foams that can be slow to respond or lose shape, the CloudSoft Core™ offers dynamic, flexible support that adapts instantly to every micro-movement. This ensures consistent comfort and alignment, whether you are a back, side, or combination sleeper. The exterior is just as thoughtfully designed. The pillow is encased in a removable, OEKO-TEX® Certified cover. This certification guarantees the fabric is free from harmful chemicals, making it hypoallergenic, breathable, and exceptionally gentle on the skin. Further enhancing its superior adaptability, the pillow features a SwitchFit™ design. This innovative feature gives users dual-height support, allowing them to simply flip the pillow to choose between a lower and a higher profile to perfectly match their body frame and sleep preference. For lasting hygiene, all materials are fast-drying and easily washable. This new Mellow Sleep cloud pillow from Mellow Sleep is now available for purchase directly from the company's website: offering an end to compromise and a new beginning for deep, restorative sleep. About Mellow Sleep: Mellow Sleep is a forward-thinking company dedicated to advancing human well-being through the science of sleep. By focusing on biomechanics, certified non-toxic materials, and user-centric design, Mellow Sleep creates innovative products that provide tangible improvements to sleep health. Their mission is to engineer a better night's sleep for a better life. Media Contact: [email protected] ### For more information about Mellow LLC, contact the company here: Mellow LLCJay Yue9293555134 [email protected] 8 The Green, Dover, DE 19901
Business Upturn
2 hours ago
- Business Upturn
TRYVIO nominated for the 2025 Prix Galien USA 'Best Pharmaceutical Product'
Allschwil, Switzerland – August 12, 2025 Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has nominated TRYVIO™ (aprocitentan) in the category of 'Best Pharmaceutical Product' in the 2025 Prix Galien USA awards. The winner will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025. To qualify for the Prix Galien Award, each candidate must be US Food and Drug Administration (FDA) approved for marketing within the last five years and demonstrate tremendous potential to improve human health. Advertisement TRYVIO, the first systemic hypertension treatment to target a new pathway in over 30 years, is a dual endothelin receptor antagonist (ERA) indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Martine Clozel, MD, Chief Scientific Officer and Head of Research atf Idorsia, commented: 'We are very proud to have been nominated for this prestigious award. TRYVIO is unique in many aspects. It is the result of many years of work on the endothelin pathway and represents a true therapeutic breakthrough with impressive clinical data. TRYVIO's blood pressure lowering effect was consistent in all studied subgroups of patients, and notably those whose hypertension is notoriously difficult to treat, such as African Americans, elderly patients, and patients with obesity or diabetes. These patients sometimes remain hypertensive despite two, three, or more anti-hypertensive therapies. Plus, TRYVIO provides significant blood pressure lowering for patients with hypertension and chronic kidney disease, a condition affecting millions of patients who are often underserved with the current guideline directed therapies, without risking aggravation of renal function or hyperkalemia.' Despite progress in improving patient outcomes, hypertension remains a major global health issue, and the number one modifiable risk factor of early morbidity/mortality, affecting an estimated 50% of adults in the US alone, with 50% of those patients not well controlled despite being on medication. These patients face significantly higher risks of cardiovascular events, including heart attack, stroke and kidney failure, and have a markedly increased risk of premature mortality compared to those with controlled blood pressure. Difficult-to-control hypertension is defined as above-goal elevated blood pressure in a patient despite the concurrent use of multiple antihypertensive drug classes. About The Prix Galien Award The Prix Galien Award recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. The Prix Galien was created in 1970 in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. For more information see the Full Prescribing Information including BOXED Warning (PI and Medication Guide). Notes to the editor About aprocitentan Aprocitentan is Idorsia's once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan is approved as TRYVIO™ in the US for the treatment of systemic hypertension in combination with other antihypertensives and has been commercially available since October 2024. Aprocitentan is approved as JERAYGO™ for the treatment of resistant hypertension in combination with other antihypertensives in the European Union and the UK and marketing authorization applications are under review in Canada, and Switzerland. About Idorsia The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact: Investor & Media Relations Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 [email protected] – [email protected] – The above information contains certain 'forward-looking statements', relating to the company's business, which can be identified by the use of forward-looking terminology such as 'intend', 'estimates', 'believes', 'expects', 'may', 'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks', 'pending' or 'anticipates' or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Wire
4 hours ago
- Business Wire
Echo and The Vitamin Outlet Partner: Bringing Hydrogen Water Health to Australians
SALT LAKE CITY & PERTH, Australia--(BUSINESS WIRE)-- Echo, a global leader in hydrogen health, has partnered with The Vitamin Outlet to launch the Echo Flask — now available to Australians seeking science-backed hydration. Echo has teamed up with The Vitamin Outlet to introduce the Echo Flask to Australia. This innovative, app-connected bottle infuses water with molecular hydrogen, offering a powerful antioxidant that supports energy, recovery, and overall cellular health. The Echo Flask is an app-connected bottle that infuses water with molecular hydrogen — a powerful antioxidant that supports energy, recovery, and cellular health. Its advanced PEM technology delivers up to 8 ppm in 20 minutes. 'We're proud to offer the Echo Flask to our customers,' said Kwong Keet Chan, CEO of The Vitamin Outlet. 'It represents a new class of hydration — safe, convenient, and scientifically validated. It fits into our mission to provide premium wellness solutions that Australians can trust.' Backed by peer-reviewed research, hydrogen water is gaining recognition for its potential to reduce oxidative stress and inflammation at the cellular level. The Echo Flask makes this wellness tool more accessible than ever. 'Australians are among the most engaged when it comes to preventative health,' said Josh Carr, CEO of Echo. 'Partnering with The Vitamin Outlet allows us to deliver an elite hydrogen wellness product to a market that values innovation and results.' Available for AUD $470, the Echo Flask is now offered through The Vitamin Outlet's website and at their Bull Creek location in Perth. Key Features of the Echo Flask Generates 5 ppm in 10 minutes, 8 ppm in 20 minutes Echo App for cycle control and hydration tracking Lightweight 350 ml design Smart touchscreen, USB-C charging Chemical-free PEM tech — no byproducts or contaminants A 5-year warranty About Echo Echo is a pioneer in hydrogen health, dedicated to helping people unlock and sustain peak performance by transforming water into a clean source of cellular support. From advanced home water systems to portable wellness solutions, Echo partners with the body to promote internal balance, resilience, and consistent energy. Backed by peer-reviewed science, trusted by health experts, and engineered for everyday living, Echo makes hydrogen health accessible, effective, and transformative. For more information, visit About The Vitamin Outlet With both an online platform and physical presence in Perth, The Vitamin Outlet is a go-to destination for trusted wellness products in Australia. It curates scientifically backed tools that help Australians live better, naturally — combining integrity, education, and service to meet the needs of today's informed consumer.
